Production (Stage)
ArriVent BioPharma, Inc.
AVBP
$20.40
-$0.23-1.12%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.09M | 15.30M | 14.87M | 13.16M | 11.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 100.41M | 94.31M | 93.72M | 86.21M | 83.09M |
| Operating Income | -100.41M | -94.31M | -93.72M | -86.21M | -83.09M |
| Income Before Tax | -127.46M | -80.49M | -81.05M | -74.89M | -74.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -127.46 | -80.49 | -81.05 | -74.89 | -74.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -127.46M | -80.49M | -81.05M | -74.89M | -74.58M |
| EBIT | -100.41M | -94.31M | -93.72M | -86.21M | -83.09M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -3.78 | -2.57 | -9.77 | -14.68 | -24.81 |
| Normalized Basic EPS | -1.62 | -1.61 | -6.10 | -9.17 | -15.51 |
| EPS Diluted | -3.78 | -2.57 | -9.77 | -14.68 | -24.81 |
| Normalized Diluted EPS | -1.62 | -1.61 | -6.10 | -9.17 | -15.51 |
| Average Basic Shares Outstanding | 134.70M | 125.85M | 94.85M | 63.87M | 32.37M |
| Average Diluted Shares Outstanding | 134.70M | 125.85M | 94.85M | 63.87M | 32.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |